CING - Cingulate Inc.

6.43
-0.130   -2.022%

Share volume: 348,598
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$6.56
-0.13
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 34%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.90%
1 Month
-10.94%
3 Months
64.03%
6 Months
71.47%
1 Year
73.78%
2 Year
435.83%
Key data
Stock price
$6.43
P/E Ratio 
0.00
DAY RANGE
$6.13 - $6.60
EPS 
-$8.24
52 WEEK RANGE
$3.20 - $7.92
52 WEEK CHANGE
$73.78
MARKET CAP 
21.217 M
YIELD 
N/A
SHARES OUTSTANDING 
6.757 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
15.99
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$320,563
AVERAGE 30 VOLUME 
$343,130
Company detail
CEO: Shane J. Schaffer
Region: US
Website: cingulate.com
Employees: 20
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cingulate Inc. focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.

Recent news